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Oxaliplatin (OXA), raltitrexed (RTX), 5-fluorouracil (FU) and folinic acid (FA) have shown activity in metastatic colorectal cancer,
radioenhancing effect and synergism when combined. We evaluated a chemotherapy (CT) combination of OXA, RTX and FU/FA
during preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC) patients. Fifty-one patients with LARC at high risk of
recurrence (T4, Nþ or T3N0 p5cm from anal verge and/or circumferential resection margin p5mm) received three biweekly
courses of CT during pelvic RT (45Gy). Surgery was planned 8 weeks after CT-RT. Recommended doses (RDs) determined during
phase I were utilised in the subsequent phase II trial, where the rate of tumour regression grade (TRG) 1 or 2 was the main end point.
No toxic deaths occurred, and severe toxicity was easily managed. In phase II, RDs delivered in 31 patients were OXA 100mgm
 2
and RTX 2.5mgm
 2 on day 1, and FU 900mgm
 2 and LFA 250mgm
 2 on day 2. Main severe toxicities by patients were grade 4
neutropenia (23%) and grade 3 diarrhoea (19%). In 71% (95% confidence limits, 52–86%) of patients, TRG1 (13) or TRG2 (9) was
obtained. All patients are alive and recurrence-free after a median follow-up of 29 months. Combination of OXA, RTX and FU/FA
with pelvic RT has an acceptable toxicity and a high clinical activity in LARC and should be studied further in patients at high risk of
recurrence.
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Total mesorectal excision (TME) has markedly improved the local
control in patients with locally advanced rectal cancer (LARC)
(MacFarlane et al, 1993). Moreover, the Dutch trial demonstrated
that the addition of preoperative radiation therapy (RT) to TME
reduced the rate of local recurrence. Nevertheless, the overall
survival (OS) was not improved because RT failed to prevent
distant metastases (Kapiteijn et al, 2001). Furthermore, preopera-
tive delivery of 5-fluouracil (FU) during RT has been proven to
further reduce the local recurrence and toxicity compared to
postoperative approach, but it did not increase recurrence-free and
OS (Sauer et al, 2004).
Raltitrexed (RTX), a direct and specific TS inhibitor (Jackman
et al, 1991), has shown activity in advanced colorectal cancer
(Cunningham, 1998). Moreover, RTX has demonstrated radio-
sensitising properties in preclinical studies (Teicher et al, 1998) as
well as activity when combined with preoperative or postoperative
RT in LARC (Botwood et al, 2000; Gambacorta et al, 2004b).
Interestingly, in vitro studies have shown a synergistic activity
when RTX is followed 24h later by FU (Longo et al, 1998;
Caponigro et al, 2001), and a positive pharmacokinetic interaction
between RTX and FU has been demonstrated (Schwartz et al,
2004). When folinic acid (FA) is added to FU in the combination,
an even greater synergism has been observed (Longo et al, 1998).
Moreover, preclinical studies have shown that the administration
of FA 24h after RTX may reduce its bone marrow and
gastrointestinal toxicity (Farrugia et al, 2000), which have been
the main life-threatening toxicities of RTX in a large multicentre
randomised trial (Maughan et al, 2002). As a matter of fact, we
have treated 53 patients with metastatic colorectal cancer with a
biweekly administration of RTX on day 1, followed by FA-
modulated FU on day 2, reporting no toxic deaths; severe
neutropenia and diarrhoea were absolutely manageable, and a
24% response rate was obtained (Comella et al, 2000).
Oxaliplatin (OXA) is a platinum derivative that has shown
radiosensitising properties (Cividalli et al, 2002), additivity with
RTX and synergism with FU (Raymond et al, 2002). Clinical
studies have shown high response rates for the combination of
OXA with either FU/FA or RTX in MCRC (Cascinu et al, 2002; Seitz
et al, 2002; Goldberg et al, 2004; Comella et al, 2005). Furthermore,
the addition of OXA to a biweekly regimen of RTX and FU/FA
proved manageable and active in heavily pretreated patients
(Comella et al, 2002). Recently, several investigators have reported
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sencouraging results with the addition of OXA to fluoropyrimidines
during pelvic preoperative radiotherapy in LARC (Gerard et al,
2003; Rodel et al, 2003; Gambacorta et al, 2004a; Aschele et al,
2005; Sebag-Montefiore et al, 2005). For all these reasons, the
combination of OXA, RTX and FU/FA with pelvic RT represents an
attractive perspective in the preoperative setting of LARC. In fact,
besides the radio-enhancing effect, this regimen takes advantage of
the synergism demonstrated between the three agents. Therefore,
we performed a phase I–II trial on the biweekly combination of
OXA, RTX and FU/FA during RT in patients with LARC.
PATIENTS AND METHODS
Eligibility criteria
Eligible patients had a histologically proven previously untreated
adenocarcinoma of the extra-peritoneal rectum. In the phase I
study, we enrolled patients in clinical stage II or III, or requiring an
abdomino-perineal resection (APR). In the phase II study, we
accrued only patients at high risk of recurrence: T4, node positive
or T3N0 of the lower third of the rectum and/or with
circumferential resection margin (CRM) p5mm by magnetic
resonance imaging (MRI) (Beets-Tan et al, 2000). Additional
inclusion criteria were Eastern Cooperative Oncology Group
performance status p2, age X18 years and adequate baseline
bone marrow and organ function. Main exclusion criteria were
previous malignant tumour, severe heart disease, uncontrolled
infection or metabolic disorders, severe neurologic or inflamma-
tory bowel disease. This study was approved by the Independent
Ethical Committee of the National Tumour Institute of Naples and
a written informed consent was obtained from all patients before
enrolment.
Work-up
Pretreatment work-up included a complete history and physical
examination, a complete blood cell count (BCC) with white blood
cell differential, a serum chemistry profile, carcinoembryonic
antigen assay (CEA), an electrocardiogram, colorectal endoscopy
with a biopsy of the tumour, transrectal ultrasonography (EUS),
chest X-ray, pelvic and abdominal computed tomography (CT)
and liver and pelvic MRI. Blood cell counts were also obtained 8
and 11 days after each cycle of chemotherapy, whereas serum
chemistry was repeated weekly.
Radiotherapy
Conformal RT was delivered by a three-field box technique,
consisting of a posterior–anterior and two lateral fields, using
high-energy X photons (6–20MV) by a Varian CD 2100 linear
accelerator, to a total dose of 45Gy over 5 weeks (1.8Gy 5
fractions/week) to the reference point according to International
Commission on Radiation Units (ICRU) 50–62. Radiation therapy
was interrupted only when a severe toxicity occurred. All patients
were treated in prone position, and a bellyboard was utilised to
minimise the amount of small bowel in the treatment field. Clinical
target volume encompassed the tumour, defined by MRI imaging,
plus the total mesorectum, the common, internal iliac and
obturatorial lymph nodes. Three-dimensional plan was performed
with a dedicated treatment planning system after on-line CT
virtual simulation and CT-MRI image fusion. We contoured the
small bowel, the femoral heads and the bladder as critical organs
on all CT slices of every patient (according to ICRU 50 and 62),
and we evaluated the relative dose–volume histogram on the
treatment planning console. A quality control was assured by a
weekly portal imaging verification of all fields, and adherence to
the protocol was checked by portal imaging verification and
matching all the fields with digitally reconstructed radiographs.
Chemotherapy
Chemotherapy consisted of three biweekly cycles delivered
immediately before RT on days 1 and 2 of the first, third and
fifth week of RT. In the first four dose levels, patients received only
RTX as short intravenous (i.v.) infusion on day 1 and levo-FA (2-h
i.v. infusion) followed by FU i.v. bolus on day 2, 24h after RTX
(Figure 1). In the next dose levels, OXA (2-h i.v. infusion) was
delivered before RTX on day 1. In case of persistent grade X2
toxicity, according to the National Cancer Institute common
toxicity criteria (NCI CTC-Version 2) at the time of recycling,
chemotherapy was delayed for 1–2 weeks. Otherwise, chemother-
apy was permanently discontinued. A 25% FU dose reduction was
applied in subsequent cycles in case of grade 4 neutropenia or
anaemia, grade X3 febrile neutropenia or thrombocytopenia,
grade X2 cardiac or renal toxicity or grade X3 other non-
haematologic toxicities (except for alopecia). At the second
appearance of these side effects or after the first appearance of
grade X3 sensory neuropathy, a 25% OXA dose reduction was also
planned. Doses of RTX and levo-FA were never reduced.
Surgery
Patients underwent TME 8 weeks after the completion of
chemoradiation. An anterior resection (AR) or an APR was
performed on the basis of restaging. Intraoperative frozen sections
were obtained to assess the resection margins in the case of
conservative treatment. Anastomoses were protected by a loop
ileostomy, and ileostomy reversal was performed after endoscopic
assessment of anastomotic integrity.
Pathology
Pathologic examination provided a macroscopic description of the
mesorectum and of the former tumour-bearing area. For residual
tumour, at least four paraffin blocks were processed, and an
additional large area block was embedded. If no tumour was
visible, the entire suspicious area was sliced and embedded.
Circumferential resection margin was examined by sampling a
1mm thick slice, and lymph nodes were searched by manual
dissection (Andreola et al, 2001a,b). All resection specimens were
examined by the same experienced pathologist, according to a
standardised protocol based on tumour node metastasis cate-
gories, reporting the number of examined and involved lymph
nodes (including the apical node one), the CRM evaluation and the
tumour regression grading (TRG). The pathologic records were
reported on a standard form for all patients.
Pathologic response was classified as follows: TRG1, complete
response with absence of residual cancer cells and fibrosis
extending through the wall (regardless of the presence of acellular
mucine lakes); TRG2, presence of few residual cancer cells
scattered through the fibrosis; TRG3, clear evidence of residual
Level 1 Level 2 Level 3 Level 4 Level 5 Level 6 Level 7
Oxaliplatin 0 0 0 0 100 120 120
Raltitrexed 2.5 2.5 2.5 2.5 2.5 3 3
5-Fluouracil 600 750 900 900 900 900 900
L-Folinic acid 250 250 250 250 250 250 250
CT days
RT days
Weeks 1    2  3    4    5 1    2  3    4    5 1    2  3    4    5
Figure 1 Treatment schedule and design of the dose finding study
(doses in mgm
 2).
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scancer cells, but with predominant fibrosis; TRG4, residual cancer
cells outgrowing fibrosis; TRG5, absence of regressive changes
(Mandard et al, 1994).
Adjuvant chemotherapy
Four months of adjuvant chemotherapy with weekly FU
370mgm
 2 and levo-FA 20mgm
 2 (QUASAR Collaborative
Group, 2000) were planned only for patients with cT4 lesions, or
with pNþ and/or pCRM p1mm.
Follow-up
Patients were clinically assessed every 3 months for the first 2
years, every 6 months for the next 2 years and annually thereafter,
with pelvic MRI, chest and abdominal CT, CEA serum level and
proctoscopy.
Study design
Phase I Based on pharmacokinetic interactions, escalation of
RTX and FU was planned only up to 3 and 900mgm
 2,
respectively (Schwartz et al, 2004). Subsequently, OXA was added
and escalated (Figure 1). Consecutive cohorts of three patients
were treated at each dose level. If a dose-limiting toxicity (DLT)
was observed, this cohort was expanded to six patients. If p2
patients out of six patients experienced a DLT at a given dose level,
escalation proceeded. Maximum tolerated dose (MTD) was defined
as the dose level at which DLTs occurred in more than one-third of
patients. Recommended dose (RD) for the subsequent phase II
study was defined as the dose level preceding the MTD. Dose-
limiting toxicities were defined as grade 4 neutropenia or anaemia;
grade X3 febrile neutropenia or thrombocytopenia; grade X2
renal and cardiac toxicity; grade X3 other non-haematologic
toxicity (except for alopecia); delay of more than 2 weeks in
chemotherapy recycling; and any other severe adverse events.
Phase II We have chosen as primary end point the achievement
of a complete or nearly complete pathologic response, because it
has been repeatedly reported to predict the long-term survival of
patients (Bouzourene et al, 2002; Ro ¨del et al, 2005; Vecchio et al,
2005). To define the sample size, a Simon’s two-stage design was
utilised (Simon, 1989), setting a and b errors as 0.05 and 0.20, and
defining as minimum activity of interest (p0) a TRG1–2
rate¼30%. To accept the alternative hypothesis (p1) of a
TRG1–2 rate X50%, at least six TRG1 or 2 in the first 15 patients,
and at least 19 TRG1 or 2 in a total of 46 patients had to be
reported. Secondary end points were safety, progression-free
survival and OS.
RESULTS
Patient characteristics
Between December 2000 and August 2004, 20 patients were
enrolled in the phase I study and 31 patients were enrolled in the
phase II study (Table 1). In the phase II study, 27 patients were at
moderately high or high risk of recurrence according to
Gunderson et al (2004). Tumour distance from the mesorectal
fascia was p5mm in 19 patients, and from the anal verge was
p5cm in 15 patients.
Dose escalation and DLTs
In the first four dose levels, no DLT occurred. With the addition of
OXA, one of three patients showed grade 4 neutropenia after the
second cycle of chemotherapy. Therefore, three more patients were
treated with this dose level. Of these last patients, a 65-year-old
women suffered from grade 3 diarrhoea, which eventually
recovered allowing for treatment completion. At the sixth dose
level, two of two patients experienced a DLT: a 77-year-old man
had a delay of more than 2 weeks after the first cycle, caused by
grade 3 neutropenia, and a 58-year-old man presented grade 3
colitis after the third cycle. Consequently, the previous dose level
was considered the RDs (Table 2).
Toxicity of the phase II study
Acute toxicities are listed in Table 3. Stomatitis, diarrhoea and
neutropenia were the only grade 3 or 4 toxicities. Grade 3
stomatitis occurred in one (3%) patient, whereas six (19%)
patients experienced grade 3 diarrhoea. Neutropenia was of grade
3 in five (16%) patients and of grade 4 in seven (23%) patients
(febrile in two patients). Only one patient required hospitalisation
for diarrhoea and concomitant grade 4 febrile neutropenia, and he
did not complete RT (cumulative dose, 41.5Gy). In all other cases,
toxicities were easily managed, and resolved in 2–4 days. Grade 1
peripheral neuropathy occurred in five (16%) patients. Eight of 93
Table 1 Characteristics of patients entered in the phase I and II studies
Characteristics Phase I, no. (%) Phase II, no. (%)
Total patients 20 (100) 31 (100)
Males 14 (70) 16 (52)
Females 6 (30) 15 (48)
Median age (years) (range) 63 (41–77) 56 (29–74)
ECOG performance status
0 9 (45) 12 (39)
1 11 (55) 17 (55)
2 0 2 (6)
Risk of failure
a and TNM clinical staging
Low risk
T1–2/N0 1 (5) 0
Intermediate risk
T1–2/N1 0 1 (3)
T3N0 8 3 (10)
Moderately high risk
T1–2/N2 0 0
T3N1 7 (35) 14 (45)
T4N0 3 (15) 0
High risk
T3N2 0 7 (23)
T4N1–2 1 (5) 6 (19)
Distance of primary tumour from anal verge
p5cm 11 (55) 15 (48)
6–10cm 8 (40) 12 (39)
410cm 1 (5) 4 (13)
Distance of tumour from mesorectal fascia
b
p5cm 3 (15) 19 (61)
45cm 3 (15) 9 (29)
Not evaluated 14 (70) 3 (10)
CEA
¼5UI 11 (55) 21 (68)
45UI 9 (45) 10 (32)
CEA¼carcinoembryonic antigen assay; ECOG¼Eastern Cooperative Oncology
Group; TNM¼tumour node metastasis.
aRisk of failure evaluated according to
Gunderson’s classification.
bEvaluated by MRI (only in patient treated with oxaliplatin).
In two patients treated in the phase I and in three patients in the phase II studies, MRI
was not performed because of metal prosthesis in four and metal stitches in the
other.
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scycles of chemotherapy were omitted for toxicity (n¼6) or refusal
(n¼2), with an RT and chemotherapy compliance of 97 and 91%,
respectively. A 25% FU dose reduction was needed in 11 patients.
Surgical morbidity
There were no intra- or postoperative deaths. Thirteen (37%)
patients treated with the RDs experienced complications, including
anastomotic fistula (n¼5), urinary fistula (n¼1), recto-vaginal
fistula (n¼1), wound dehiscence (n¼1), presacral abscess (n¼1),
minimal anastomotic stenosis (n¼3) and anastomotic leakage (in
a male patient who refused loop ileostomy). Only one patient
required additional surgery.
Activity
Phase I All 20 patients underwent R0 resection, but liver
metastases were diagnosed intraoperatively in two patients. A
TRG1 was obtained in six (30%) patients and a TRG2 in two (10%)
patients.
Phase II All patients had a TME with complete mesorectum, and
the median number of retrieved nodes was 29 (range 10–80).
Twenty-nine (93%) patients had an R0 resection, because CRM
was p1mm in two patients. Anterior resection was performed in
25 patients, and a sphincter-preserving procedure could be
performed in nine of 15 (60%) patients with tumour located
p5cm from the anal verge. In two patients, APR was mandatory
because of baseline sphincter infiltration. Twenty-five patients
(81%) obtained a T downstaging (four of six cT4, 19 of 23 cT3 and
two of two cT2). Nodal downstaging was detected in 23 of 28 (82%)
patients. Positive lymph nodes were detected in only five (16%)
patients, one of whom with a single micrometastatic focus. No
patient showed an increase of T or N stage. Pathologic evaluation
showed a TRG1 in 13 (42%) patients and a TRG2 in nine (29%)
patients. Therefore, a TRG1 or 2 was reported in 71% (95%
confidence limits, 52–86%) of patients, with no significant
correlation with baseline clinical characteristics (Table 4).
Follow-up
As of November 2005, after a median follow-up of 53 (range
41–59) months, four patients recruited in the phase I study
Table 2 Toxicity by dose levels
NCI-CTC grade
Dose levels 1–4 Dose level 5 Dose level 6
(n¼12) (n¼6) (n¼2)
Toxicity Grade 1/2 Grade 3 Grade 4 Grade 1/2 Grade 3 Grade 4 Grade 1/2 Grade 3 Grade 4
Haematologic
Neutropenia 2 1 2 1 2
Febrile neutropenia 1
Thrombocytopenia 1 1 1
Gastrointestinal
Nausea/vomiting 7 2
Colitis 2 1
Diarrhoea 1 3 1 1
Stomatitis 1 1
Proctitis 1 1
Genitourinary
Cystitis 1
Skin, local toxicity 1
Fatigue/asthenia 1
Fever 1
NCI-CTC¼National Cancer Institute Common Toxicity Criteria. Note: Most severe toxicity of each type experienced by each patient.
Table 3 Worst toxicities by patients reported in the phase II study
NCI-CTC grade
Grade 1 Grade 2 Grade 3 Grade 4
Toxicity no. (%) no. (%) no. (%) no. (%)
Haematologic
Neutropenia 4 (13) 1 (3) 5 (16) 5 (16)
Febrile neutropenia 1 (3) 2 (6) 2 (6)
Thrombocytopenia 2 (6) 3 (10)
Gastrointestinal
Nausea/vomiting 11 (35) 4 (13)
Colitis 1 (3) 2 (6)
Diarrhoea 2 (6) 5 (16) 6 (19)
Stomatitis 1 (3)
Proctitis 3 (10) 2 (6)
Skin, local toxicity 1 (3) 2 (6)
Fatigue/asthenia 3 (10) 1 (3)
Fever 1 (3) 2 (6)
Paresthesia/dysesthesia 5 (16)
NCI-CTC¼National Cancer Institute Common Toxicity Criteria.
Table 4 Correlation between pretreatment clinical characteristics and
pathological findings in the phase II study (n¼31)
TRG1–2 TRG3–4
Clinical characteristics (number of patients) no. (%) no. (%)
cTNM staging – Gunderson risk of failure
T1–2/N1; T3N0 – intermediate 3 (75) 1 (25)
T1–2/N2; T3N1; T4N0 – moderately high (14) 11 (79) 3 (21)
T3N2; T4N1–2 – high (13) 8 (61) 5 (39)
Distance of primary tumour from anal verge
¼5cm (14) 11 (79) 3 (21)
45cm (17) 11 (65) 6 (35)
Distance of tumour from mesorectal fascia
a
¼5mm (19) 15 (79) 4 (21)
45mm (9) 6 (67) 3 (33)
TNM¼tumour node metastasis.
aMRI was not performed in three patients, for the
presence of metal prosthesis (two patients) and metal stitches (one patient).
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shad a distant recurrence (only one had received OXA)
and four patients had died (two patients for cancer-unrelated
causes). All 31 patients of the phase II study are alive and
recurrence-free after a median follow-up of 29 (range 16–41)
months.
DISCUSSION
The results of a recent randomised trial, combining FU with local
RT, have further supported preoperative vs postoperative treat-
ment of LARC, but have also raised several issues (Sauer et al,
2004). In particular, the lack of reduction of distant metastases in
this trial strongly supports the exploitation of more active
cytotoxic regimens. Moreover, the risk of overestimating the
tumour’s degree of penetration with EUS points to the need for a
more accurate staging of patients. Furthermore, retrospective data
have suggested that a combined modality therapy could represent
an overtreatment in patients at low risk of local failure after TME
alone, such as some tumours staged as T3N0 (Willett et al, 1999).
In this setting, MRI plays a key role, because it can predict the
CRM involvement (Beets-Tan et al, 2000), so defining the patients
at higher risk of local recurrence when treated with TME plus RT
(Marijnen et al, 2003), although it has been demonstrated less
sensitive and specific at identifying nodal disease and vascular
invasion (Brown et al, 2003; Branagan et al, 2004).
Our phase I–II study was carried out in patients with LARC at
high risk of recurrence, as identified by both EUS and MRI. The
aim of the phase I study was to determine the MTDs of the
combination of RTX, FU/FA and OXA combined with pelvic RT.
Raltitrexed and FU were escalated only up to 3 and 900mgm
 2,
respectively, because a pharmacokinetic analysis has demonstrated
that pre-administration of RTX (X2.5mgm
 2) 24h before FU
(900mgm
 2) significantly increased its Cmax and AUC (Schwartz
et al, 2004).
A grade 3 neutropenia was the only severe toxicity that occurred
in the first four dose levels. The safety of the administration of
RTX plus FU during RT could likely be explained by the
concurrent delivery of FA. Indeed, preclinical studies have shown
that the administration of FA 24h after RTX not only reduced its
toxicity (Farrugia et al, 2000) but also increased the synergism
between RTX and FU (Longo et al, 1998). When OXA was added to
the combination, the RDs for the phase II study were OXA 100mg
m
 2, RTX 2.5mgm
 2, FU 900mgm
 2 and LFA 250mgm
 2,
administered every 2 weeks. Notably, these dosages are similar or
even greater than those usually utilised in the treatment
of metastatic colorectal cancer patients without RT (Cascinu
et al, 2002; Seitz et al, 2002; Goldberg et al, 2004; Comella et al,
2005).
Neutropenia and diarrhoea were the most frequent grade 3 or 4
adverse events occurring in the phase II study. However, we would
underline that in our experience, the occurrence of grade X3
neutropenia was similar to that reported in the MOSAIC trial with
FOLFOX4 regimen (Andre ´ et al, 2004), and severe diarrhoea was
not higher than that seen in the CAO/AIO/ARO-94 trial with
preoperative RT plus FU (Sauer et al, 2004). Moreover, in all but
one case, toxicity resolved in 2–4 days without hospitalisation.
Neurotoxicity was negligible and scored as grade 1 only. The
favourable toxicity profile of this combined treatment was
reflected by its high compliance and by the acceptable surgical
morbidity, with only one patient requiring re-operation.
In the phase II study, we have analysed the pathologic response
using the TRG score, because it has been shown to be more
accurate in defining the tumour regression after primary therapy,
and to predict the long-term outcome (Bouzourene et al, 2002;
Ro ¨del et al, 2005; Vecchio et al, 2005). Notably, the number of
TRG1 or 2 required by our statistical design had already been
reached in the first 31 treated patients, with an overall activity
(71%) by far greater than that hypothesised. In addition, such
activity has never been reported with preoperative combination
chemotherapy and RT (Gerard et al, 2003; Rodel et al, 2003; Mehta
et al, 2003; Gambacorta et al, 2004a; Aschele et al, 2005; Sebag-
Montefiore et al, 2005). The 95% confidence limits of these results
(52–86%) strongly support the conclusion that this approach
could be effective in at least half of treated patients. Moreover, it
should be stressed that the complete or nearly complete pathologic
response rate was obtained in high-risk patients (Phang et al, 2002;
Gunderson et al, 2004). Interestingly, the achievement of TRG1–2
was independent of baseline characteristics. The high activity of
this treatment was reflected by the per cent of R0 resection (93%),
as well as tumour and nodal downstaging (81 and 82%,
respectively). Moreover, 84% of patients showed no nodal
involvement, no T or N upstaging was observed, and sphincter
preservation was obtained in 60% of patients with low-lying
tumours.
One could argue whether a similar activity could be obtained
without the inclusion of RTX in the combination. Indeed, several
recent phase I–II trials have explored the activity of a combination
of OXA and fluoropyrimidines (i.v. FU or oral capecitabine)
during preoperative pelvic RT (Gerard et al, 2003; Rodel et al,
2003; Aschele et al, 2005; Sebag-Montefiore et al, 2005). Although
all these trials have demonstrated the feasibility of such combina-
tions, we would underline that the reported pCR rates (ranging
between 7 and 28%) were clearly lower than that achieved in our
study. Notably, in all these studies, the OXA dose intensity during
radiotherapy ranged from 43 to 60mgm
 2 per week, which is
similar to that we were able to deliver with our three-drug
combination.
On the other hand, a phase II study integrating three cycles of
OXA and TOM (without FU/FA) with pelvic RT has reported a pCR
in 9 out of 30 (30%) LARC patients (Gambacorta et al, 2004a).
However, it should be noted that only patients with a limited
disease extent (not including T4) were treated in this study. On the
contrary, our treatment yielded a 42% TRG1 in an unfavourable
patient population.
Furthermore, we would point out the accurate pathologic
evaluation we performed, which allows a critical assessment of
the primary treatment, and may facilitate interstudy comparison.
Indeed, an accurate pathologic analysis allows one to assess the
CRM involvement, the number of examined and involved lymph
nodes and the quality of surgical performance, providing valuable
data that have an impact on outcome (Tepper et al, 2001;
Nagtegaal et al, 2002; Mawdsley et al, 2005). It is important to
stress that in our study, the resection of mesorectum was complete
in all patients, CRM was p1mm in only two patients and a median
number of 29 nodes was retrieved.
Finally, it is remarkable that after a median follow-up of 29
months, all patients of the phase II study are alive and recurrence-
free. Of note, only 11 of these patients have received post-resection
adjuvant FU/FA.
In conclusion, this study demonstrates that the combination of
OXA, RTX and FU/FA with pelvic RT in LARC patients has an
acceptable toxicity and an excellent treatment compliance. More-
over, it provides evidence of high clinical activity in patients
selected for high risk of recurrence. On these bases, we have
decided to complete patient accrual up to the planned sample size,
testing a slight dose reduction of FU (800mgm
 2) to further
improve the safety of this combined treatment.
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